Of these, 3 patients had 3 SAEs in the vedolizumab group that were considered as treatment related by the study investigator (pancytopenia, pyrexia, and bronchopulmonary aspergillosis), and 2 patients had 3 SAEs in the placebo group considered as treatment related (atypical mycobacterial infection, pneumonia, and increased alanine aminotransferase). The gene discussed is GPT; the disease is susceptibility to pneumonia measurement.